INTRODUCTION
Progeria is a genetic disorder rarely encountered and is charac terized by features of premature aging. It is also known as "Hut chin sonGilford Progeria syndrome" (1) . Although signs and symptoms vary in age of onset and severity, they are remark ably consistent overall. Children with HGPS usually appear nor mal at birth. Profound failure to thrive occurs during the first year (2) . Characteristic facies, with receding mandible, narrow nasal bridge and pointed nasal tip develop. Motor and mental development is normal. Death occurs as a result of complications of severe atherosclerosis, either cardiac disease (myocardial in farction) or cerebrovascular disease (stroke), generally between ages 6 and 20 yr. Average life span is approximately 13 yr (2) .
We report here a 4yrold boy with an apparently typical Hut chinson-Gilford progeria syndrome with G608G LMNA muta tion.
CASE DESCRIPTION
A 4yrold boy was referred to the department of pediatrics with short stature and sclerodermatous skin on 2 September 2010. He was the first child born to nonconsanguinous parents with no significant family history. He was born at full term with birth weight of 3.35 kg by spontaneous virginal delivery. His abnormal appearance was not found at birth. At age of 1 yr, growth retar dation, hair loss, and alteration of skin color on the abdominal region began.
On physical examination, his length was 88 cm and weight 11.5 kg, both less than 3rd percentile and head circumference was 52 cm (ca. 77th percentile) (Fig. 1) . He had generalized in durated and shiny skin associated with decreased subcutane ous fat, especially on the abdomen. His hair was fine and sparse and his scalp veins were easily visible (Fig. 1) . His anterior fon tanelle was still patent (horizontal diameter 1.7 cm, vertical di ameter 1.4 cm). He had craniofacial disproportion for his age due to micrognatia, prominent eyes, scant eyelashes and small nose. His bone age was 3 yr. He was neurologically intact with motor and mental development. On serological and hormonal evaluation, all values are within normal range. An echocardio gram did not show concentric left ventricular hypertrophy nor increased left ventricular pressure but showed calcification of aortic and mitral valves (Fig. 2) . Hypertrophy of internal layer at internal carotid artery suggesting atherosclerosis was found by carotid doppler sonography (Fig. 2) . He is on low dose aspirin to prevent thromboembolic episodes and on regular follow up.
We obtained his DNA from white blood cell in peripheral blood and sequencing was performed by such method as belows; Sam ples were extracted using a MG TM Tissue Kit. We designed poly merase chain reaction (PCR) primers using the Primer 3 pro gram. The primers Tms ranged between 59°C and 62°C as far as possible. The PCR reaction was performed with 20 ng of genom ic DNA as the template in a 30 µL reaction mixture by using a EFTaq (SolGent, Korea) as follows: activation of Taq polymerase at 95°C for 2 min, 35 cycles of 95°C for 1 min, 55°C63°C, and 72°C for 1 min each were performed, finishing with a 10 min step at 72°C. The amplification products were purified with a multi screen filter plate (Millipore Corp., Bedford, MA, USA). Sequenc ing reaction was performed using a PRISM BigDye Terminator v3.1 Cycle sequencing Kit. The DNA samples containing the ex tension products were added to HiDi formamide (Applied Bio systems, Foster City, CA). The mixture was incubated at 95°C for 5 min, followed by 5 min on ice and then analyzed by ABI Prism 3730XL DNA analyzer (Applied Biosystems, Foster City, CA, USA). The results were analyzed using the software DNA star (http://www.dnastar.com). Gene study showed typical G608G (GGC > GGT) point mu tation at exon 11 in LMNA gene (Fig. 3) . He had a younger sister with normal appearance. we planned to carry out gene study for her and his family but couldn't for their refusal. After the di agnosis, he regularly visits our clinic for routine lab., echocardio gram and carotid doppler sonography. In addition, with our help, he was enrolled in The Progeria Research Foundation (PRF) in USA and is waiting for farnesyltransferase inhibitors (FTIs) for clinical trials.
DISCUSSION
Progeria was described for the first time in 1886, by Hutchinson, and ratified by Gilford, in 1904. It occurs sporadically, with an incidence of 1 in 8 million live births and there are approximate ly 150 cases described in the medical literature. It predominates in males with a ratio of 1.5:1 and greater susceptibility of Cauca sians can be seen in 97% of cases (3). In Korea, 5 cases were re ported in the medical literature (49). This is the first case diag nosed as HutchinsonGilford Progeria syndrome by gene study in Korea.
Children with HGPS look so similar that they could all be mis taken for siblings. There is variability in onset and rate of pro gression of disease among children, although the final pheno type in these patients is remarkably similar, underscoring the identical common mutation that leads downstream to similar pathobiology (10) . In this syndrome, the rate of aging is acceler ated up to seven times that of normal. The average life span is 13 yr (range 727 yr), but occasionally can survive till the age of 45 yr. The death is mainly due to cardiovascular complications like myocardial infarction or congestive heart failure. The evi dence supports the de novo point mutations in lamin A (LMNA) gene as the causative factor has been increasing (11) .
The most common HGPSassociated mutation, Gly608Gly, causes 150 nucleotides encoded in exon 11 to be spliced out of the final mRNA and results in a protein that lacks 50 amino ac ids. This protein, progerin, retains its Cterminal CAAX motif but lacks sequences that are required for complete processing and is, therefore, stably farnesylated (12) . Lamin A is a protein meshwork lining the nucleoplasmic face of the inner nuclear membrane and represents an important determinant of inter phase nuclear architecture (13) . Progerin apparently acts in a dominantnegative manner on the nuclear function of cell types that express Lamin A (14) . The increased progerin causes nu clear blebbing and altered shape of the nucleus.
The clinical manifestations are divided into major criteria and signs usually presents itself as follows: the major criteria are a birdlike face (which occurs around 6 months to one year of age), alopecia, prominent veins on the scalp, big eyes, micrognathia, abnormal and slow dentition, pearshaped chest, short clavi cles, bow legs (coxa valga), short upper limbs and prominent articulations, low stature and weight with normal bone age, in complete sexual maturation, reduction of the adipose tissue and adequate psychomotor development with normal intelligence. Diagnosis is essentially clinical with major criteria appearing during the first and second years of life (15) . Cutaneous mani festations are earlier to appear followed by skeletal and cardio vascular systems. In our case, cardiovascular systems showed calcification of aortic and mitral valves and hypertrophy of in ternal layer at internal carotid artery suggesting atherosclerosis. Skeletal abnormalities include osteolysis, osteoporosis, dystro phic clavicles, coxa valga, "horse riding" stance, thinning of cra nial bones, delayed closure of cranial sutures and anterior fon tanelle.
Prognosis is detrimental to the health of the patient and life expectancy is around 13 yr. The main mortality factors are car diovascular diseases (75%) like acute myocardial infarction. De spite the advances in cardiovascular surgery, the low survival rate remains due to the high capacity of the disease to reproduce the erythematous plaques. Lowdose aspirin is recommended as prophylaxis to prevent atherosclerotic changes (15) .
A vigorous research effort in the pharmaceutical industry has identified and developed a number of smallmolecule com pounds that potently and selectively inhibit farnesyltransferase (FTase). In vitro studies in mice suggest a possible role for the use of farnesyltransferase inhibitors (FTIs) in progeria (15) . Farne sylation, a posttranslational modification involving the addition of a 15carbon isoprene moiety, was implicated as a potential anticancer target when it was discovered that the oncoprotein Ras, which has been estimated to be involved in up to 30% of all human cancers, required farnesylation for its function. Two of these drugs (lonafarnib_SCH66336 from ScheringPlough, Ke nilworth, NJ, and tipifarnib_R115777 from Johnson & Johnson, New Brunswick, NJ) have entered phase III trials and have been well tolerated, including in trials involving children (16) . Lona farnib competes with protein substrates for binding to the FTase enzyme (17) . Similar to Ras, the Lamin A precursor is also farne sylated, with farnesylation serving as a required step to insert prelamin A into the nuclear membrane as well as to allow for the two downstream cleavage steps which complete the pro cessing of Lamin A (18) . For this patient, we are waiting for FTIs for clinical trials.
With the knowledge that the single CtoT base change seen in nearly all cases of HGPS created a cryptic splice site and, thus, deleted the normal second endoproteolytic cleavage site in the Lamin A processing pathway, it was hypothesized that progerin was forced to retain its farnesyl group and, therefore, could not dissociate itself from the nuclear membrane. With other mem bers of the nuclear lamina also potentially becoming trapped in complexes with the mislocalized progerin, a mechanistic con nection between this permanently farnesylated state and the striking nuclear blebbing and disrupted nuclear architecture seen in HGPS cells was proposed, and the possibility of prevent ing or reversing this phenotype through FTIs was raised. Detailed study of HGPS and LMNA mutations may also advance our un derstanding of the process of aging. Why do LMNA mutant cells enter senescence earlier than normal cells? (19) .
In summary, we found a new patient with typical Hutchin sonGilford Progeria syndrome with mutation of the G608G in the LMNA gene. This is the first case diagnosed as Hutchinson Gilford Progeria syndrome by gene study in Korea.
